Abstract
SummaryThe treatment paradigm for locally advanced rectal cancer has changed in recent years. Neoadjuvant radiochemotherapy followed by total mesorectal excision and postoperative chemotherapy has been the standard of care since many years. With this multidisciplinary approach the local recurrence rate is low, but the occurrence of distant metastases and impairments of quality of life due to bowel, bladder, and sexual dysfunction are still unresolved problems. The integration of induction or consolidation chemotherapy into the neoadjuvant setting, a watch-and-wait strategy without surgery for patients with clinical complete response, the integration of immunotherapy into the neoadjuvant setting in microsatellite-instable rectal cancer as well as the selective omission of neoadjuvant radiotherapy now represent different treatment options and enable individualization of therapy for locally advanced rectal cancer. Here, we provide an overview of the latest developments in the treatment of locally advanced rectal cancer and a discussion on which patients need more intensive or less intensive therapy.
Funder
Johannes Kepler University Linz
Publisher
Springer Science and Business Media LLC
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献